clinical trial · NCT03066011
Registry of Patients Treated With Systemic Mold-Active Triazoles
Astellas Pharma Global Development, Inc.·—·completed·n = 2,015
Invasive Fungal InfectionIsavuconazonium sulfateVoriconazolePosaconazole
brief summary
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).
started
Mar 16, 2017
primary completion
Apr 24, 2020
completion
Apr 24, 2020
last updated
Oct 21, 2024
official title
Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol